DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SOTAC PHARMACEUTICALS LTD (SOTAC) share price today?

SOTAC PHARMACEUTICALS LTD (SOTAC) is trading at ₹95.1 on the NSE, down 4.90% on the day. Source: DocStoX.

What is the PE ratio of SOTAC PHARMACEUTICALS LTD?

SOTAC PHARMACEUTICALS LTD has a price-to-earnings (PE) ratio of 18.2 in the Healthcare sector.

What is the market capitalisation of SOTAC PHARMACEUTICALS LTD?

SOTAC PHARMACEUTICALS LTD has a market capitalisation of approximately ₹0 crore.

SOTAC PHARMACEUTICALS LTD

SOTAC·NSE·Healthcare

₹95.10▼ -4.90 (-4.90%)

Healthcare · Pharmaceuticals

A steady, established business

52W₹95

₹1400%

Open

₹95.10

High

₹95.10

Low

₹95.10

Prev Close

₹100.00

Volume

2.4K

VWAP

₹95.10

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

18.22Fair

P/B Ratio

1.89

EPS

₹5.22

Book Value

₹53.30

ROE

10.30%Average

ROCE

13.00%Decent

Dividend Yield

0.10%

Debt / Equity

0.64Moderate

Face Value

₹10.00

52W High

₹139.65

52W Low

₹95.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹58

▼ 39.1%downside

Trading at ₹95 — 39% above our estimate

BearFair valueBull

₹49₹58₹79

/100

Business quality — Solid

Growth 69Profitability 24Efficiency 13Valuation 74

Plain English

Our view

A steady, established business
Profit growing 44% a year
Fundamental red flags (Piotroski 1/9)

Strengths

Profit growing 44% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

10% ROE fading to 13% over ~3 yrs, on ₹53 book

₹52

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹79

Analyst target

No analyst coverage

—

Blended fair value₹58

What the numbers say

Investment thesis

Bull case

Profit growing 44% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

18.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

10.3%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.64Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

1.89

EPS

₹5.22

Div Yield

0.10%

What changed

Recent changes

Foreign investors+16.8% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 18.2×

Growth

Steady

+9% rev CAGR

Profitability

Modest

10.3% ROE

Financial health

Comfortable

D/E 0.64

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹2.28L Cr

Trades2

VWAP₹95.10

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.5%

+15.6%

10Y

—

Profit

+44.2%

—

10Y

—

EPS

+13.4%

—

10Y

—

Profile

Pros

Company has delivered good profit growth of 34.7% CAGR over last 5 years

Watch-outs

Cons

Company has a low return on equity of 13.0% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 16.79 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

73%

Promoter

Promoters

72.8%0.00

Public

6.5%+1.39

FII / FPI

16.8%+16.79

DII

0.0%0.00

Others

3.8%

Total shareholders

221-19 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter72.85%

FII16.79%

Public6.52%

Others3.84%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2015, Sotac Pharmaceuticals Ltd manufactures and sells a wide range of pharmaceutical products[1]